Genmab-developed sclerosis treatment beats competition in small injector pen study

Following the approval of sclerosis drug Kesimpta, originally from Genmab, Novartis is positioning this drug against its competitors. New study shows patients' and health personnel's impression of the firm's special injector pen compared with treatments from Teva, Biogen and Merck.
Photo: Brian Snyder/Reuters/Ritzau Scanpix
Photo: Brian Snyder/Reuters/Ritzau Scanpix
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

Novartis has, in a recent study, examined sclerosis patients' impressions of the firm's autoinjector pens used to administer its medication.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading